MedTrace Logo

Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Patients With Amyotrophic Lateral Sclerosis

NCT02881489 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-08-29

No results posted yet for this study

Summary

The goal of this study is to investigate the safety and tolerability of autologous bone marrow-derived mesenchymal stem cells administration in the individuals with diagnosed amyotrophic lateral sclerosis.

Conditions

Interventions

OTHER

Biological: Cell-based therapy

Human autologous bone marrow-derived mesenchymal stem cell transplantation in ALS patients.

Sponsors & Collaborators

  • University of Warmia and Mazury

    lead OTHER

Principal Investigators

  • Wojciech Maksymowicz, MD, Prof. · Faculty of Medical Sciences, University of Warmia and Mazury in Olsztyn, Poland

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2018-04-30
Completion
2018-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02881489 on ClinicalTrials.gov